ampelopsin has been researched along with Diabetic Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, J; Guo, H; Lin, H; Lin, N; Lu, W; Ni, T; Sun, Z | 1 |
| Fan, M; Guo, T; Han, D; Lin, J; Luo, J; Tao, L; Wu, B; Yi, F; Yuan, M | 1 |
2 other study(ies) available for ampelopsin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Proteins; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Down-Regulation; Flavonols; Male; Mice; MicroRNAs; Myocytes, Cardiac; Rats, Wistar; Signal Transduction; Ventricular Function, Left | 2020 |
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice.
Topics: Animals; Apoptosis; Autophagy; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Flavonols; Inflammation; Male; Mice; Oxidative Stress | 2017 |